STUDY OF CLINICAL MANIFESTATIONS AND OUTCOME OF RTPCR NEGATIVE COVID PNEUMONIA PATIENTS RECEIVING INJECTION REMDESIVIR.

Atharva Ajay Kulkarni*, Meenakshi Ashesh Bhattacharya, Sandesh Malu, Shrutika Kamble and Omkar Oak

ABSTRACT

Background: RTPCR is considered gold standard for diagnosis but because of False Negatives, HRCT scans are used as an aid for radiological diagnosis of COVID-19. Remdesivir is an antiviral pro-drug used to treat COVID-19 positive cases. But there are no treatment options for patients presenting as COVID pneumonia but testing negative by RTPCR. Methods add Period: We conducted a cross sectional observational study to find the outcome of RTPCR Negative Pneumonia patients receiving Remdesivir. Between June 2020 to January 2021, patients who tested negative after an RTPCR swab for SARS-CoV2 but were clinically or radiologically suspected to have COVID-19 were administered Remdesivir (200 mg on day one followed by 100 mg for the next four days) and their outcome, with demographic, clinical and radiologic characteristics of COVID-19 were assessed. Results: Out of 158 RTPCR Negative Pneumonia patients who received Remdesivir, 150 recovered (94.9%) and were discharged. 95 patients (60.12%) were Males. 61 patients belonged to age groups between 40-59 years (38.6%) and 65 patients were of the age ≥60 years (41.1%). 54 patients (34.1%) had some comorbidity, Hypertension being the most common, in 37 patients (23.4%). 91 patients (57.5%) belonged to Stage IIB. 39 patients (24.6%) had oxygen saturation <80% at admission of which 35 were discharged giving a recovery rate of 89.7%. Conclusion: It was observed that 94.9% RTPCR Negative COVID-19 pneumonia who received Inj. Remdesivir recovered and were discharged.

Keywords: COVID-19, RTPCR, Negative, Pneumonia, Remdesivir.